Clinical trial

VK2735 for Weight Management Phase 3

Active, not recruiting · Phase 3 · 2 countries · Registry ID NCT07104500

Active, not recruitingPhase 3Interventional

What this study is about

This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to Not listed
SexAll
Healthy volunteersNot accepted
ConditionWeight Loss

Full registry criteria

Inclusion Criteria: 1. Age ≥18 years of age at the time of signing the informed consent 2. Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co- morbid condition (treated or untreated) * Weight-related co-morbid conditions include hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease * Cardiovascular disease includes, for example, ischemic cardiovascular disease, New York Heart Association (NYHA) Functional Class I-III heart failure * BMI calculated at the Screening visit will be used to determine eligibility Exclusion Criteria: 1. History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation 2. Self-reported body weight change of 5% or more within 3 months of screening 3. Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty if performed \>1 year prior to screening) 4. Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as, mucosa ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line) 5. Current or past diagnosis of diabetes mellitus (including type 1, type 2, except gestational diabetes) 6. Treatment with glucose-lowering agent(s) within 90 days before screening 7. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) 8. History of acute or chronic pancreatitis

Treatments and study arms

VK2735

Drug

VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly

Primary outcomes

Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment78 Weeks

Study locations

137 locations were listed when this page was built. The first 40 are shown.

Viking Clinical Site #1130🇵🇷 Mayagüez, Puerto Rico
Viking Clinical Site #1086🇵🇷 San Juan, Puerto Rico
Viking Clinical Site #1047🇺🇸 Abilene, Texas, United States
Viking Clinical Site #1088🇺🇸 Albany, New York, United States
Viking Clinical Site #1029🇺🇸 Albuquerque, New Mexico, United States
Viking Clinical Site #1098🇺🇸 Arlington, Virginia, United States
Viking Clinical Site #1116🇺🇸 Atlanta, Georgia, United States
Viking Clinical Site #1007🇺🇸 Austin, Texas, United States
Viking Clinical Site #1063🇺🇸 Austin, Texas, United States
Viking Clinical Site #1118🇺🇸 Baton Rouge, Louisiana, United States
Viking Clinical Site #1139🇺🇸 Baton Rouge, Louisiana, United States
Viking Clinical Site #1091🇺🇸 Bellaire, Texas, United States
Viking Clinical Site #1037🇺🇸 Birmingham, Alabama, United States
Viking Clinical Site #1064🇺🇸 Birmingham, Alabama, United States
Viking Clinical Site #1103🇺🇸 Boston, Massachusetts, United States
Viking Clinical Site #1124🇺🇸 Brownsville, Texas, United States
Viking Clinical Site #1010🇺🇸 Butte, Montana, United States
Viking Clinical Site #1005🇺🇸 Chandler, Arizona, United States
Viking Clinical Site #1141🇺🇸 Charlotte, North Carolina, United States
Viking Clinical Site #1094🇺🇸 Chevy Chase, Maryland, United States
Viking Clinical Site #1006🇺🇸 Chicago, Illinois, United States
Viking Clinical Site #1090🇺🇸 Chicago, Illinois, United States
Viking Clinical Site #1071🇺🇸 Chula Vista, California, United States
Viking Clinical Site #1043🇺🇸 Cincinnati, Ohio, United States
Viking Clinical Site #1074🇺🇸 Cincinnati, Ohio, United States
Viking Clinical Site #1031🇺🇸 City of Saint Peters, Missouri, United States
Viking Clinical Site #1013🇺🇸 Clearwater, Florida, United States
Viking Clinical Site #1121🇺🇸 Clearwater, Florida, United States
Viking Clinical Site #1044🇺🇸 Cleveland, Ohio, United States
Viking Clinical Site #1030🇺🇸 Columbus, Georgia, United States
Viking Clinical Site #1089🇺🇸 Columbus, Ohio, United States
Viking Clinical Site #1003🇺🇸 Cooper City, Florida, United States
Viking Clinical Site #1048🇺🇸 Dallas, Texas, United States
Viking Clinical Site #1049🇺🇸 Dallas, Texas, United States
Viking Clinical Site #1112🇺🇸 DeLand, Florida, United States
Viking Clinical Site #1107🇺🇸 Delray Beach, Florida, United States
Viking Clinical Site #1119🇺🇸 Denver, Colorado, United States
Viking Clinical Site #1122🇺🇸 Durham, North Carolina, United States
Viking Clinical Site #1045🇺🇸 East Greenwich, Rhode Island, United States
Viking Clinical Site #1042🇺🇸 East Syracuse, New York, United States